Program
PRTX007
A development code.
Its studies are mostly in Melanoma, led by Primmune Therapeutics.
Furthest: phase 2, since Apr 20, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Primmune Therapeutics | 11 open or running | phase 2since Apr 20, 2026 | Apr 20, 2026 | Dec 2027phase 2 · NCT07565285 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 20, 2026First study: phase 2 study in MelanomaFirst studyNCT07565285 · 48 planned · Australia
Ahead
- Dec 2027Primary completion: phase 2 study in MelanomaNCT07565285
TargetBeta
TLR7 →read by rule
“Participants will receive oral PRTX007, a Toll-like receptor 7 (TLR7) agonist prodrug, administered in combination with intravenous pembrolizumab prior to surgical resection.”study text, by rule · the study
Other programs on TLR7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resiquimodrule | Staidson (Beijing) Biopharmaceuticals | phase 3 | 14 |
| enpatoranrule | Merck KGaA, Darmstadt, Germany | phase 3 | 12 |
| afimetoranrule | Bristol-Myers Squibb | phase 3 | 12 |
| TLR7 Agonist JNJ-64794964 | Sino Biopharmaceutical | phase 2 | 6 |
| Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102rule | united-immunity-co-ltd | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07565285Melanoma · Australia | 2 | Recruiting | Dec 2027 | 48 |
How it is read
Names in the registry
- “PRTX007”, 1 entry
Codes read as this program: PRTX007.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.